FOLH1 and posterior cortical atrophy: Among them, [68Ga]PSMA-11 and [18F]DCFPyL with ureido-glutatamate-based PSMA-targeting ligands have been approved for PSMA-targeted PET imaging in men with PCa by the Food and Drug Administration (FDA) in 2020 [8].